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ABSTRACT 
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significant delays 
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Primary central nervous system lymphoma (PCNSL) is a very aggressive non-Hodgkin 
lymphoma. It restricts to the central nervous system and has a low survival rate while 
responding well to radiation and chemotherapy. The immunohistochemical profile, mutation 
analysis, cytokines from cerebrospinal fluid (CSF) and oedema occurring might have diagnostic 
and prognostic value when suspecting PCNSL. PCNSL has a lower mass effect, leading to less 
oedema compared with same size other tumours such as gliomas or metastases.  
PCNSL reacts favourably to glucocorticoids, such as dexamethasone, but they might also 
interfere with the diagnosis, leading to delay in the diagnostic path. This is something that 
requires assessment in the future. An oedema and its mass effect grading system could help 
with decision to refrain from dexamethasone usage if lymphoma is suspected. The longest delay 
causing factor in OYS and KYS was waiting for the biopsy. This problem could be dealt with 
the possibility to do on-call biopsy or with the CSF fluid analysis leading to diagnosis. 
 




Primaariaivolymfooma on aggressiivinen non-Hodginin lymfooma, joka rajoittuu 
keskushermostoon. Kuolleisuus on korkea huolimatta usein hyvästä alkuvaiheen säde- ja 
sytostaattihoitovasteesta. Diagnoosi perustuu immonohistokemiallisiin tutkimuksiin ja 
tarvittaessa mutaatioanalyyseihin. Aivolymfoomilla on yleensä pienempi massavaikutus ja 
vähemmän aivoturvotusta kuin glioomilla tai aivometastaaseilla. Primaariaivolymfooma reagoi 
hyvin glukokortikoideihin, kuten dexametasoniin, mutta ne voivat merkittävästi vaikeuttaa ja 
viivästyttää diagnostiikkaa. Tämä tarvitsee jatkotutkimuksia. Aivoturvotuksen ja sen 
massaefektin luokittelujärjestelmä voisi auttaa dexametasonin käytöstä pidättäytymisessä, 
mikäli epäillään aivolymfoomaa. Pisimmän viiveen aiheuttava tekijä OYS:ssä ja KYS:ssä oli 
biopsian odottaminen. Tämä ongelma voitaisiin välttää päivystysbiopsian mahdollisuudella tai 
likvorin analytiikan tehostamisella.  
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Primary central nervous system lymphoma (PCNSL) is an uncommon type of extranodal non-
Hodgkin lymphoma, which means that it occurs outside of the lymph node area (Grommes & 
DeAngelis, 2017). It is extremely aggressive and restricted to the central nervous system (CNS). 
Apart from the brain and spine, it can also be found on cerebrospinal fluid (CSF) and eyes. 
While it has a favourable response to radiation and chemotherapy, survival is generally lower 
compared to systemic lymphomas. PCNSL can develop in both immunosuppressed and 
immunocompetent patients. Majority of PCNSLs are diffuse large B-cell lymphomas (DLBCL) 
(Grommes & DeAngelis, 2017). 
 
The incidence rates of PCNSL are increasing, especially in patients older than 60 years, with a 
rate of 0.5 per 100 000 per year (Grommes & DeAngelis, 2017). In the United States, around 
1 500 new patients are diagnosed every year. In the Oulu University Hospital, the rate is 0.44-
0.87 per 100 000 per year which means around 24-47 new patients every year (Kuittinen & 
Kuitunen, 2017). A remarkable risk factor for the development of PCNSL is immunodeficiency, 
including iatrogenic immunosuppression, congenital disorders and especially HIV (Villano, 
Koshy, Shaikh, Dolecek, & McCarthy, 2011). Among immunocompetent patients, the mean 
age of occurrence is from 53 to 57 years, while in immunocompromised patients it is from 31 





2 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA 
 
2.1 Clinical presentation 
 
Patients with PCNSL develop various neurologic signs such as notable neurologic deficits, 
changes in behavioural and mental status, seizures and symptoms that occur when intracranial 
pressure is increased, including headaches, nausea and vomiting (Grommes & DeAngelis, 
2017). However, the symptoms depend on the part of the CNS involved. In most cases PCNSL 
is a single brain lesion located in the supratentorial area, involving frontoparietal lobes. 
Involvement of the spinal cord is rare and lesions in eyes and CSF are also less frequent. Spinal 
cord lymphoma mimics the symptoms of myelopathy which may include cauda equina and 
paresthesis (Flanagan et al., 2011). Symptoms vary depending on the segment involved.  
 






Usually, magnetic resonance imaging (MRI) exposes a homogeneously increasing mass lesion 
(Grommes & DeAngelis, 2017). The tumour is typically in contact with meningeal and 
ventricular surfaces with the involvement of the supratentorial brain (Mansour, Qandeel, 
Abdel-Razeq & Hussain, 2014).  
 
Mansour et al. (2014) studied specific MRI findings in immune competent patients suffering 
from intracranial PCNSL. They discovered that T1- and T2-weighted images typically present 
a homogenous mass with high-cellular signal intensity due to hypercellularity and high 
nuclear/cytoplasmic ratio. Necrosis, internal calcification and haemorrhage are atypical and 
rare characteristics of PCNSL. When typical imaging findings are absent, new imaging 
techniques such as magnetic resonance spectroscopy (MRS), perfusion-weighted imaging (PWI) 
and diffusion-weighted imaging (DWI) have important role in the diagnosis of PCNSL. 
 
Differential diagnosis of PCNSL from other tumours is important because as corticosteroids 
are effective in reducing the oedema caused by the tumour, they may also reduce the size of the 
PCNSL leading to significant delays in diagnosis. Supratentorial location in addition to contact 
with meningeal and ventricular surfaces, absence of haemorrhage, necrosis and internal 
calcification should raise suspicion of PCNSL.  
 





Image 2. T2-weighted MRI of the right frontal lobe PCNSL without (left) and with 




Image 3. T1-weighted MRI of the right frontal lobe PCNSL without (left) and with 












In addition to MRI, diagnosing PCNSL requires ophthalmologic and CSF evaluation. The 
establishment of the diagnosis includes stereotactic biopsy, which is a golden standard of the 
PCNSL diagnosis. However, the availability of operating rooms cand of the on-call biopsy can 
cause delays in the diagnosis of PCNSL, as it is at present at the Oulu University Hospital 
(OUH). When there is eye or CSF manifestations of the PCNSL, only vitrectomy or CSF 
cytology might be enough (Grommes & DeAngelis, 2017).   
 
2.4 Immunohistochemical staining/Histopathology 
 
Histologically, PCNSL is a diffuse growing tumour with characteristic angiocentric infiltration 
pattern, where tumor cells form cuffs around blood vessels (Bhagavathi & Wilson, 2008). 
Tumour cells are large and atypical with distinct nucleoli, corresponding to centroblasts or 
immunoblasts, which are mature B-cells with CD20-positive phenotype. Expression of BCL-2 
is typical and most tumours express BCL-6 and MUM-1 as well. CD10 is expressed in less than 




lymphomas (DLBCLs) (Deckert, Brunn, Montesinos-rongen, Terreni, & Ponzoni, 2014). The 




Treatment of PCNSL includes chemotherapy, high doses of methotrexate and radiotherapy 
(Bhagavathi & Wilson, 2008). It also responses dramatically to corticosteroids, but that is 
usually temporary. The genetic characterization of the lymphoma helps in individualization of 
the treatment (Hottinger, Alentorn, & Hoang-Xuan, 2015). In half of the patients, the results 
are durable, but late neurotoxicity can be associated with the treatment (Grommes & DeAngelis, 
2017). 
 
University hospital of Oulu is the only hospital in Finland which offers blood-brain barrier 
disruption treatment to PCNSL. Therefore, many patients from across the country are sent to 




Age and the status of performance preoperatively are the most important prognostic factors 
apart from the therapy. There are also other factors that could be evaluated to predict the 
outcome of the treatment, including the level of lactate dehydrogenase, the concentration of 
CSF protein and the involvement of the deep brain. Molecular markers indicating phenotype 
and mutations might help in understanding the development and mechanisms of PCNSL and 





3 PCNSL AND DIAGNOSTIC MARKERS 
 
3.1 Immunohistochemical profile 
 
The expression of immunohistochemical (IHC) markers might have potential prognostic 
significance in PCNSL (Liu et al., 2017). In the analysis of 89 cases, the prognostic significance 
of various biological markers was evaluated with overall survival (OS) and progression-free 
survival (PFS). These markers were cluster of differentiation (CD)10, B-cell lymphoma (BCL)-
6, multiple myeloma-1 (MUM-1), BCL-2, CD138, and Ki-67. The study suggests that high Ki-
67 expression may be associated with poor prognosis in PCSNL because it was associated with 
shorter overall survival (OS) and progression free survival (PFS). Any other IHC markers listed 
were not significantly associated with either OS or PFS, suggesting that these markers might 
not have a prognostic value. However, this study was limited by the number of cases analysed 
and the short follow-up time.  
 
Ki-67 and BCL-2 are proteins that are overexpressed in diffuse large B-cell lymphoma (DLBCL) 
and one study suggests that the BCL2/Ki-67 ratio is a very effective prognostic factor on 
patients with DLBCL (Tang, Zhou, Cheng, Su, & Wang, 2017). Ki-67 is used as an index to 
evaluate the lymphoma’s proliferative activity because it synthesizes at the beginning of cell 
proliferation. BCL-2 functions in antiapoptotic signalling by inhibiting programmed cell death.  
 
In OYS, pathologist performs intraoperative frozen section diagnostic with H&E and toluidine 
blue staining. If a quick immunohistochemical staining is needed, CD45 staining specially 
prepared for the frozen section analysis can be used to identify the lymphocytic cells. In final 
diagnosis, a routine immunohistochemical staining protocol including CD3, CD20, BCL-2, 
BCL-6, CD10, MUM-1 and Ki-67 is performed to the formalin fixed paraffin embedded tissue.  
No mutation analysis is performed. In some cases in this research, minor IHC staining protocol 












Table 1. Immunohistochemical markers and their relevance 
Marker Value 
BCL-6 Prognostic significance is controversial. Might predict favourable outcome in DLBCL 
because its positivity indicates an improved course of disease. (Liu et al., 2017) 
MUM-1 Typical feature of PCNSL but doesn’t have prognostic significance. (Liu et al., 2017)l 
BCL-2 Important independent survival predictor in patients with DLBCL, although the association 
between BCL-2 and prognosis is inconclusive. (Liu et al., 2017) 




Significant prognostic value. Cases with MYC-BCL-2 co-expression has remarkably 
worse overall survival. (Shi et al., 2017) 
IL-10 Might predict therapeutic response and severity of PCNSL. Combines reliable diagnostic 
biomarker together with increased IL-10/IL-6 level (Song et al., 2016) 
IL-10/IL-6 ratio Important parameter in differential diagnosis, especially for central nervous system 
infections. (Song et al., 2016) 
 
 
3.2 Cerebrospinal fluid 
 
Biomarkers in the cerebrospinal fluid (CSF) for PCNSL and liquid biopsies from the CSF could 
be used in the diagnosis of PCNSL. Cytokine interleukin-10 (IL-10) inhibits apoptosis and 
promotes proliferation of B lymphoma cells, and thereby it has a role in the development of 
lymphoma (Song et al., 2016). One study used electrochemiluminescence immunoassay 
(ECLIA) to determine the cytokine levels and the results demonstrate identically increased IL-
10 levels in all patients with PCNSL. Moreover, in some cases the post-chemotherapy CSF IL-
10 levels decreased, accompanied by disease remission. This suggests that IL-10 levels could 
be used in defining the state of the disease. 
 
Over 70 abnormal genes have been reported in PCNSL, including CD79B and MYD88, which 
are clinically useful because those can be directly targeted in the therapy (Hiemcke-Jiwa et al., 
2018). MYD88 affects the Toll-like receptor (TLR) pathway and CD79B affects the B-cell 
receptor (BCR) pathway. Together these combine on the NFκB pathway. As a result, IL-6 and 
IL-10 are produced, leading to cell proliferation. Mutations in the MYD88 lead to incorrect 
activation of TLRs, including TLR4, TLR5, and TLR9 (Akhter et al., 2015). In this study, 85% 
of DLBCL cases expressed high amounts of TLR9 compared with normal B-lymphocytes. It is 




transformation, tumor cell maintenance, and progression. These pathways could be targeted in 
future therapies. 
 
When PCNSL is suspected, the patient is admitted to the neurosurgery unit and a CSF sample 
is collected if it is not contraindicated (Graph 1). Flow cytometry analysis is performed to the 
CSF sample and if positive, the tissue biopsy is not needed. CSF diagnosis is expected to 
indicate correct diagnosis up to 25% of the patients with PCNSL and in this case unnecessary 
tumour biopsy can be avoided. If CSF flow cytometry analysis is negative it is necessary to 
continue to the stereotactic biopsy. 
 
Table 2. Mutations and their effect on outcome in PCNSL (Hiemcke-Jiqa et al., 2018) 
Gene Function Number of 
patients with 
aberration 




CD79B BCR complex, NFκB pathway activation 22/42 Mutation 
MYD88 TLR, NFκB pathway activation 33/42 Mutation 
CARD11 BCM complex, NFκB pathway activation 8/42 Mutation 
TBL1XR1 Co-factor in transcription, Regulation of ETV6 
activity, negative modulation of TLR/MYD88 
signalling 
10/42 Mutation 
TNFAIP3 (A20) Tumour necrosis factor (TNF) mediated 
apoptosis, inhibition of NFκB pathway  
5/42 Mutation 
CDKN2A (TP16) Essential in genomic stability, tumour suppressor, 
control of cell-cycle phase G1 





ETV6 Transcriptional repressor, need for development 
of vascular network and haematopoiesis, role in 
malignant transformation 
1/18 (Braggio et 
al., 2015) 
Mutation 
PIM1 Protein kinase, which is involved in survival and 
proliferation of cells, a target of somatic 
hypermutation  
29/42 Mutation 













May serve as additional and/or alternative 
modulator of the MYD88/TLR signalling 
pathway, increased TLR activity 












Perilesional oedema is a common characteristic of PCNSL, occurring in more than 90% of 
cases. PCNSL still has a lower mass effect when compared with same size metastases or 
malignant gliomas (Mansour, Qandeel, Abdel-razeq, Ali, & Ali, 2014). This information might 





4 OYS AND KYS DIAGNOSTIC PATHS WITH DELAYS IN EACH 
PHASE 
 
4.1 Materials and methods 
 
The aim of this study was to analyse the efficiency of the diagnosis and treatment path of the 
primary nervous system lymphoma (PCNSL) and to identify delay causing factors in the 
diagnostic path and in the starting of the cytostatic treatment. Research data consists of patients 
who were diagnosed with PCNSL in Oulu University Hospital (OUH) or Kuopio University 
Hospital (KUH) in the period between years 2000-2019. The data was collected from patient 
records. The efficiency of the diagnostic path was estimated with mean delays between each 
phase of the diagnostic path (Table 3). The phases are emergency room visit, imaging, biopsy, 
diagnosis and the beginning of the cytostatic treatment.  
 
The patient dependent delay was not taken into account in these delays because of the lack of 
ability to detect when the symptoms had started if the emergency room visit was not needed 
due to the situation being rather chronic than acute. The number of cases vary in the delay 
analysis due to the missing date in the patient records or because every patient didn’t undergo 
every phase. Almost every patient needed on-call imaging because of the symptoms, except 





The mean delays from the first emergency room visit to the confirmed diagnosis were 48.52 
days in OUH and 22.67 in KUH. The longest delay in diagnostic path in OUH was the delay 
from first emergency room (ER) visit to imaging and the second longest was from the imaging 
to biopsy. The reason why the latency from ER visit to imaging is so long is because this n 
number included those whose lymphoma presented only as eye symptoms, so it took longer 
time to realize that the cause of eye symptoms was lymphoma. After excluding those patients, 
the mean delay from ER visit to imaging in OUH was only 2.36 days.  
 
Table 4 shows diagnostic delays after removing rare delaying factors such as non-diagnostic 
biopsy, eye symptoms treated as something else than lymphoma, tumour not seen in CT 




standard diagnostic delays, which is 18.20 days in OUH and 18.45 days in KUH. Long delays 
and their causes are discussed later. 
 
Table 3. Diagnostic delays in different parts of the diagnostic path without excluding. 







Delay from first emergency room visit to 
imaging 
76 17.75 55 22.87 21 4.33 
Delay from imaging to biopsy 81 20.70 58 23.55 23 13.52 
Delay from biopsy to diagnosis 86 3.37 63 2.83 23 4.87 
Delay from first emergency room visit to 
diagnosis 
77 41.47 56 48.52 21 22.67 
Delay from diagnosis to the beginning of 
cytostatic treatment 






Table 4. Delays in different parts of the diagnostic path after excluding patients with 
massive delays in diagnostic path.  







Delay from first emergency room 
visit to imaging 
64 2.52 44 2.36 20 2.85 
Delay from imaging to biopsy 68 13.16 47 14.11 21 11.05 
Delay from biopsy to diagnosis 73 3.23 52 2.63 21 4.71 
Delay from first emergency room 
visit to diagnosis 
65 18.28 45 18.20 20 18.45 
Delay from diagnosis to the 
beginning of cytostatic treatment 






The main delay causing factor in OUH is waiting for the biopsy, being 14.11 days (Table 4, 
Delay from imaging to biopsy). Also, unpleasant delay causing factor may be preoperative 
dexamethasone. In cases discussed below there are examples, where dexamethasone caused 
improve in the symptoms after the tumor was detected on the CT. Unfortunately, in these cases 
it could have shrunk the tumour so that there was not a target big enough for the biopsy to be 
taken. In the future, it would be important to make a list of PCNSL imaging characteristics in 
order to avoid prescribing dexamethasone if lymphoma is suspected, which could make the 
diagnosis established faster. Also, it would be essential to define dexamethasone dosage which 
would help with the perilesional oedema, but it wouldn’t shrink the tumour neither clean up the 
CSF from tumour cells, and thus wouldn’t interfere with the diagnosis. This would decrease 
inconvenience caused by the lack of on-call biopsy. 
 
Among the study patients there was one case in which the delay from symptoms to diagnosis 
was only two days because it was possible to make the diagnosis from the CSF analysis. There 
was no dexamethasone administered prior to the lumbar puncture. This patient had the 
cytostatic treatment started in six days after the symptoms occurred, which was an extraordinary 
short time delay. 
 
In KUH the overall time from symptoms to diagnosis was significantly lower than in OUH, but 
after excluding 13 patients with massive delaying factors the mean delay was similar, being 
18.20 days in OUH and 18.45 days in KUH. Also, in KUH on-call biopsy was available, which 
shortened the time from imaging to biopsy in some patients. In OUH, the intraoperative frozen 
section of the tumour was analysed by the pathologist during the surgery, which shortened the 
delay of the diagnosis. At the beginning of the study period there was no intraoperative frozen 
section diagnostics done in KUH, but later it started to be used. 
 
The mean delay from diagnosis to the beginning of the cytostatic treatment was 7.36 days in 
OUH and 11.79 days in KUH. Usually, treatments required Rickham reservoir, which is a 
catheter inserted into the cerebral ventricles with injection reservoir for percutaneous punctures.  
This was sometimes inserted during the same anesthesy after the frozen section diagnosis 





5 CASES WITH SIGNIFICANT DELAYS IN DIAGNOSIS AND WHAT 
CAUSED THEM  
 
Table 5 lists cases of extreme delays in diagnosis. In group 1, the main factor causing the delay 
was a failed biopsy. Among these patients only one out of five didn’t use dexamethasone. In 
group 2, CT imaging didn’t reveal the tumour but fortunately, MRI did. In group 3, the lesion 
disappeared and reappeared later. In this group, all patients were using preoperative 
dexamethasone. In group 4, first PCNSL symptoms were eye symptoms, the patients were 
treated as having vitritis first. In group 4, the treatment time varied from few months to years. 
In this group, it was unclear whether there was an infection first which predisposed to the 
genesis of lymphoma, or if the cause of the symptoms was a lymphoma from the beginning, 
with misdiagnosis and wrong treatment. However, it caused distort to the diagnostic times, so 
it was considered better to analyse these cases separately.  
 
The delay from imaging to biopsy in group 1 and 2 shows, that if lesion disappears or the biopsy 
is nondiagnostic, it leads to extremely long delays in establishing of correct diagnosis. Even 
though the number of cases in these groups is limited (n=13), it is something to consider 
whether to take a risk with dexamethasone usage and possibly longer diagnostic delay, when it 
comes to such an aggressive disease as primary central nervous system lymphoma. 
 
Table 5. The reasons for long delays. 






















Delay from first emergency room 
visit to imaging 
5 6.80 1 6.00 3 7.00 3 375.6
7 
Delay from imaging to biopsy 5 94.40 2 27.50 3 72.67 3 12.33 
Delay from biopsy to diagnosis 5 6.60 2 3.00 3 1.67 3 3.33 
Delay from first emergency room 
visit to diagnosis 





Delay from diagnosis to the 
beginning of cytostatic treatment 







Since PCNSL is a very aggressive disease (Grommes & DeAngelis, 2017), thus it is important 
to optimize the diagnostic path. As seen in Table 4, the longest delay was caused by waiting for 
the biopsy. The CSF analysis could make biopsy unnecessary (Hiemcke-Jiwa et al., 2018), but 
it may require refraining from dexamethasone even though it has negative effect on the patient’s 
symptoms. Hiemcke-Jiwa et al. also suggests, that in the absence of malignant cells or cells 
being too lytic for flow cytometry analysis, it could be beneficial to do the cytokine analysis of 
CSF or search for miRNA. The CSF samples of patients in our research undergone only flow 
cytometry analysis.  
 
The PCNSL requires CT and MRI grading system, so it would be easier to make a decision to 
refrain from the dexamethasone and other glucocorticoids when lymphoma is suspected. The 
effect of the corticosteroids on the diagnosis of the PCNSL is a wildly discussed matter. In the 
analysis of 54 cases (Bullis et al., 2019), 18 patients had preoperative dexamethasone and only 
one patient had nondiagnostic tissue biopsy. These results suggest that short course of 
preoperative corticosteroids would not interfere with tissue biopsy diagnosis. They suggest that 
a second preoperative MRI could confirm the size and presence of the tumour when 
corticosteroids are used. This research was limited by the number of the cases included. Another 
study (Deckert et al., 2014) suggests that preoperative corticosteroids are a substantial clinical 
problem, and that they have been shown to prevent diagnosis in up to 50% patients. However, 
further research is needed whether the positive CSF fluid analysis remains positive after the 
corticosteroid usage, since the CSF has a lower cell count than the tumour from the beginning.  
 
Among this research’s patient group, nearly everyone’s cytostatic treatment started with Bonn 
protocol. Starting cytostatic treatment already in the operative room as soon as positive frozen 
section result has arrived, could be considered in orher to shorten the delay from the diagnosis 
to the initiating of the treatment. In addition, the starting of the cytostatic treatment could also 
be faster by installation of Rickham reservoir simultaneously with stereotactic biopsy in cases 
of positive intraoperative frozen section. Since waiting for the biopsy already causes delay to 
the diagnosis, it would be essential to minimalize the delay from the diagnosis to the starting of 





Patients with persistent eye problems, such as vitritis, could benefit from early performed 
vitrectomy, so that possible lymphoma is differentiated from other eye diseases at as early stage 
as possible and the prognosis could be better without unnecessary delay in the diagnosis. 
Another option could be to perform MRI to detect possible asymptomatic brain lesion as soon 
as suspicion of lymphoma arises. 
 
This research identified delays in the diagnostic path. The latest studies in this field have also 
been focused in making the diagnosis faster and safer for the patient. Many researchers are 
interested in the possibilities of the CSF analysis and have been discussing the benefits of the 
liquid CSF biopsy compared with the tissue biopsy, which is the golden standard of the 
diagnosis. While the CSF diagnosis holds promising research possibilities for the future, it still 







The most significant delay in the diagnostic path of the PCNSL was waiting for the biopsy. 
This could be avoided by the CSF analysis which could make biopsy unnecessary. However, 
further research on the CSF diagnostic is needed due to the fact that right now its sensitivity is 
relatively low. In the Table 6 below is listed delay causing factors and possible solutions which 
could minimize them. 
 
Table 6. Possible delay causing factors identified in this research and solutions to their 
minimalization. 
Possible delay causing factor Possible solution 
Waiting for the biopsy On-call biopsy possibility 
 
CSF analysis leading to diagnosis 







Refraining from dexamethasone usage 
because it might clean the CSF from 
lymphoma cells. 
 
Cytokine analysis of CSF. 
 
Second preoperative MRI 
Dexamethasone usage possibly leading to a 
delay in the diagnosis 
Better identification of lymphoma. 
 
An oedema and its mass effect grading 
system which could help identify lymphoma. 
Waiting for cytostatic treatment Installation of Rickham reservoir 
simultaneously with stereotactic biopsy in 
case of positive intraoperative biopsy. 
 
A standardized starting dose of the cytostatic 





A CT-negative tumour Simultaneous magnetic resonance imaging in 
case of normal CT and severe or long lasted 
clinical symptoms 
Eye manifestation of lymphoma treated as 
eye infection 
Definition of criteria in collaboration with 
ophthalmologists on when to perform 
vitrectomy to exclude possible lymphoma if 
eye symptoms persist. 
 
Definition of criteria when to perform MRI 
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